Gemcitabine in NK/T Cell Lymphoma

Samsung Medical Center

Status: Completed

Conditions: NK/T Cell Lymphoma

Study type: Observational

Funder types: Other

Identifiers

NCT01660568

2012-07-043

Details and patient eligibility

About

We retrospectively review patients with refractory or relapsed ENKL who received a gemcitabine-containing regimen

Enrollment: 20 patients

Sex: All

Ages: 15+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• NK/T cell lymphoma
• relapse or refractory disease
• gemcitabine containing treatment

Exclusion Criteria:

Trial design

20 participants in 1 patient group

relapsed or refractory NK/T cell lymphoma with gemcitabine